David Michael Johnson

CIK: 0001808098

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

ZNTL

Zentalis Pharmaceuticals, Inc.

Director

AURA

Aura Biosciences, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

ZNTL
Zentalis Pharmaceuticals, Inc.
Jun 16, 2026
Award(A)
Direct
57.1K shares-
AURA
Aura Biosciences, Inc.
Jun 11, 2026
Award(A)
Direct
15K shares-
ZNTL
Zentalis Pharmaceuticals, Inc.
Jun 17, 2025
Award(A)
Direct
57.6K shares-
AURA
Aura Biosciences, Inc.
Jun 17, 2025
Award(A)
Direct
13K shares-
AURA
Aura Biosciences, Inc.
May 16, 2025
Purchase(P)
Direct
20K shares at avg. $4.90$98K

		Type	Shares	Price		Ownership
Jun 16, 2026	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	57,100	-	$0	Direct
Jun 11, 2026	AURA Aura Biosciences, Inc.	Award(A)	15,000	-	$0	Direct
Jun 17, 2025	ZNTL Zentalis Pharmaceuticals, Inc.	Award(A)	57,603	-	-	Direct
Jun 17, 2025	AURA Aura Biosciences, Inc.	Award(A)	13,000	-	-	Direct
May 16, 2025	AURA Aura Biosciences, Inc.	Purchase(P)	20,000	$4.90	$98,000	Direct

1-5 of 5 transactions

About Johnson David Michael

Johnson David Michael (SEC CIK 0001808098) files insider reports with the SEC as Director of Zentalis Pharmaceuticals, Inc. (ZNTL) and Director of Aura Biosciences, Inc. (AURA).

Signal8 holds 5 ownership filings by Johnson David Michael, all Form 4s, filed between May 20, 2025 and Jun 18, 2026. Those filings report 5 transactions, from May 16, 2025 to Jun 16, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Johnson David Michael's filings is in BOSTON, MA.

Recent filings by Johnson David Michael

Jun 16, 2026: Grant or award of ZNTL shares (Form 4, code A).
Jun 11, 2026: Grant or award of AURA shares (Form 4, code A).
Jun 17, 2025: Grant or award of ZNTL shares (Form 4, code A).
Jun 17, 2025: Grant or award of AURA shares (Form 4, code A).
May 16, 2025: Open-market purchase of AURA shares (Form 4, code P).

Other insiders filing for Zentalis Pharmaceuticals, Inc. (ZNTL)

Bruns Ingmar, Chief Medical Officer
WALTERS GROUP, 10% Owner
Skvarka Jan, Director
Walker Luke Nathaniel, Director
Kariuki Enoch, Director
Myers Scott Dunseth, Director

How to read Form 4 transaction codes